Neuraly

Neuraly is a company with a goal to develop potential first-in-class disease modifying agents for neurodegenerative diseases. Neuraly’s lead asset NLY001, is a proprietary long-acting peptide for Parkinson’s disease (PD) and Alzheimer’s disease (AD). PD is the 2nd most common neurodegenerative disorder that affects about one million Americans with no curative therapy options available. NLY001 is a potential disease modifying drug for PD with proven pharmacological efficacies in clinically relevant and complementary PD preclinical models. NLY001 demonstrates synergistic anti-inflammatory and neuroprotective effects in the brain and inhibits abnormal alpha-synuclein (?-Syn) fibril formation believed to be the originator of PD.